Week in Review: Tattoos and imaging | NHS imaging delays | The great AI debate

Dear AuntMinnie Europe member,

The U.K. Imaging and Oncology (UKIO) congress was held this week in Liverpool and former AuntMinnie Europe Editor-in-Chief Philip Ward was on hand to provide our coverage. 

His article on the impact of tattoo pigments on x-rays was our most highly read story of the week. Also, you won’t want to miss his report from the plenary session, which featured a nearly two-hour discussion on the current status of AI in radiology and the main challenges that lie ahead. Signify Research CEO and co-founder Steve Holloway also shared his thoughts on the subject in a video interview after the debate.

AuntMinnie Europe members were also interested in learning that nearly two million patients in England are waiting for diagnostic tests.

As part of our continuing coverage of SERAM 2026, we’ve got a report on how biparametric MRI can save time and money in prostate cancer imaging. And early FAPI-PET/CT scans can yield equivalent performance to standard 60-minute scans for lung cancer staging.

AI was a popular topic on AuntMinnie Europe this week. New research has found that AI can enhance risk prediction on cardiac MRI and may provide early breast cancer alerts from mammograms.

Please see below for our other top stories from the week.

Erik L. Ridley
Editor in Chief
AuntMinnieEurope.com

1.     Tattoo pigments can have significant impact on imaging

2.     1.92M patients waiting for NHS diagnostic tests in England

3.     The great AI debate: Expensive failure or vital prerequisite?

4.     SERAM 2026: Biparametric MRI cuts time and costs in prostate cancer imaging

5.     Early FAPI-PET scans match 60-minute scans for lung cancer staging

6.     AI gives a boost to cardiac MRI risk prediction

7.     AI may provide early breast cancer alerts from mammograms

8.     ECIO 2026: Interventional oncology’s next step

9.     MMA embolization for chronic subdural hematoma: Routine takes shape

10.  What’s the optimum approach for B3 breast lesions?

Page 1 of 7
Next Page